All patients
metastasis (liver ) previous nephrectomy (no) previous nephrectomy (yes) Risk favorable (IMDC) Risk favorable (MSKCC) Risk intermediate (IMDC) Risk intermediate (MSKCC) Risk poor (IMDC) Risk poor (MSKCC)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
renal cell cancer (RCC), atezolizumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias progression or deaths (PFS)detailed results IMmotion-150 (At - all population), 2018 1.19 [0.82; 1.72]
IMmotion-150 (At - PDL1>1%), 2018 1.03 [0.63; 1.68]
IMmotion-150 (AtB - all population), 2018 1.00 [0.69; 1.45]
IMmotion-150 (AtB - PDL1>1%), 2018 0.64 [0.38; 1.08]
0.98 [0.78 ; 1.24 ] IMmotion-150 (At - all population), 2018, IMmotion-150 (At - PDL1>1%), 2018, IMmotion-150 (AtB - all population), 2018, IMmotion-150 (AtB - PDL1>1%), 2018 4 18% 630 moderate not evaluable objective responses (ORR)detailed results IMmotion-150 (At - all population), 2018 0.80 [0.43; 1.48]
IMmotion-150 (At - PDL1>1%), 2018 1.06 [0.46; 2.42]
IMmotion-150 (AtB - all population), 2018 1.15 [0.63; 2.10]
IMmotion-150 (AtB - PDL1>1%), 2018 2.34 [1.05; 5.20]
1.18 [0.77 ; 1.80 ] IMmotion-150 (At - all population), 2018, IMmotion-150 (At - PDL1>1%), 2018, IMmotion-150 (AtB - all population), 2018, IMmotion-150 (AtB - PDL1>1%), 2018 4 32% 630 moderate not evaluable AE (any grade)detailed results IMmotion-150 (At - all population), 2018 0.51 [0.05; 5.72]
IMmotion-150 (AtB - all population), 2018 2.03 [0.07; 61.21]
0.81 [0.11 ; 5.81 ] IMmotion-150 (At - all population), 2018, IMmotion-150 (AtB - all population), 2018 2 0% 404 moderate not evaluable AE (grade 3-4)detailed results IMmotion-150 (At - all population), 2018 0.30 [0.17; 0.53]
IMmotion-150 (AtB - all population), 2018 0.78 [0.43; 1.40]
0.48 [0.19 ; 1.23 ] IMmotion-150 (At - all population), 2018, IMmotion-150 (AtB - all population), 2018 2 81% 404 moderate not evaluable AE leading to death (grade 5)detailed results IMmotion-150 (At - all population), 2018 0.97 [0.13; 7.02]
IMmotion-150 (AtB - all population), 2018 1.50 [0.25; 9.17]
1.23 [0.32 ; 4.68 ] IMmotion-150 (At - all population), 2018, IMmotion-150 (AtB - all population), 2018 2 0% 404 moderate not evaluable TRAE (any grade)detailed results IMmotion-150 (At - all population), 2018 0.21 [0.07; 0.65]
IMmotion-150 (AtB - all population), 2018 0.38 [0.11; 1.25]
0.28 [0.12 ; 0.63 ] IMmotion-150 (At - all population), 2018, IMmotion-150 (AtB - all population), 2018 2 0% 404 moderate not evaluable TRAE (grade 3-4)detailed results IMmotion-150 (At - all population), 2018 0.15 [0.08; 0.29]
IMmotion-150 (AtB - all population), 2018 0.49 [0.28; 0.87]
0.27 [0.08 ; 0.89 ] IMmotion-150 (At - all population), 2018, IMmotion-150 (AtB - all population), 2018 2 87% 404 moderate not evaluable TRAE leading to death (grade 5)detailed results IMmotion-150 (At - all population), 2018 0.24 [0.01; 5.37]
IMmotion-150 (AtB - all population), 2018 0.49 [0.04; 5.49]
0.37 [0.06 ; 2.52 ] IMmotion-150 (At - all population), 2018, IMmotion-150 (AtB - all population), 2018 2 0% 404 moderate not evaluable Colitis TRAE (grade 3-4)detailed results IMmotion-150 (At - all population), 2018 0.98 [0.02; 49.90]
IMmotion-150 (AtB - all population), 2018 0.99 [0.02; 50.39]
0.99 [0.06 ; 15.86 ] IMmotion-150 (At - all population), 2018, IMmotion-150 (AtB - all population), 2018 2 0% 405 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMmotion-150 (At - all population), 2018 0.98 [0.02; 49.90]
IMmotion-150 (AtB - all population), 2018 0.99 [0.02; 50.39]
0.99 [0.06 ; 15.86 ] IMmotion-150 (At - all population), 2018, IMmotion-150 (AtB - all population), 2018 2 0% 405 moderate not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-20 21:53 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 10,93,79,178,152,80
- treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866
